GSK has announced encouraging findings regarding a new treatment for gynecological cancers as its CEO, Luke Miels, intensifies the company’s focus on drug development.<\/p>\n
The firm reported that in an early-phase clinical trial, Mocertatug Rezetecan, referred to as Mo-Rez, was able to reduce or eliminate tumors in 62% of patients with ovarian cancer who had not responded to chemotherapy, and in 67% of patients with endometrial cancer.<\/p>\n
Headquartered in London, GSK has recently received recognition for its efforts in combating superbugs, becoming one of only three major pharmaceutical companies worldwide that continue to invest in antimicrobial research.<\/p>\n
However, GSK has faced commercial challenges in recent years, overshadowed by its larger British competitor AstraZeneca, which surpassed GSK\u2019s nearly \u00a333 billion revenue by over \u00a310 billion last year. AstraZeneca also played a significant role in developing one of the first Covid-19 vaccines during the pandemic in collaboration with Oxford University, whereas GSK, despite its expertise in vaccines, was slower to engage.<\/p>\n
In late 2023, GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from Hansoh Pharma in China, and has conducted trials with 224 patients globally, including in the UK, over the past year. Only a few patients discontinued treatment due to side effects, the most frequently reported being nausea.<\/p>\n
With these results, combined with data from a separate intermediate trial conducted in China, GSK is poised to advance directly to late-stage trials, planning five clinical studies worldwide in the coming months, including participation from UK patients.<\/p>\n
During a presentation at the Society of Gynecologic Oncology\u2019s annual meeting on women\u2019s cancer in Puerto Rico, Hesham Abdullah, GSK\u2019s global head of cancer research and development, remarked, \u201cAddressing gynecological cancers remains a significant challenge, and there is an urgent need for new therapies that demonstrate better response rates. Mo-Rez provides us with compelling evidence of its promising clinical profile.\u201d<\/p>\n
Globally, endometrial cancer impacts 1.6 million women, with 417,000 new diagnoses each year, while ovarian cancer affects 843,000 individuals, resulting in 240,000 new cases annually.<\/p>\n
In discussions with reporters prior to the conference, Abdullah characterized Mo-Rez as a \u201ckey asset\u201d in GSK’s expanding cancer portfolio, anticipating that it could become a blockbuster drug with peak annual sales exceeding \u00a32 billion. This would significantly contribute to GSK’s goal of reaching \u00a340 billion in sales by 2031.<\/p>\n
Miels, an Australian executive who joined GSK from AstraZeneca in 2017 under former CEO Emma Walmsley, has initiated several strategic partnerships since taking over leadership on January 1. He has committed to demonstrating \u201cscientific courage.\u201d<\/p>\n
Abdullah noted that Miels, with whom he previously collaborated at AstraZeneca, has accelerated the pace of drug development. \u201cThe entire organization is enjoying this rapid pace, agility, and the scientific courage that he fosters,\u201d he stated.<\/p>\n
In recent years, GSK has re-entered the oncology field after divesting its cancer portfolio to Novartis in 2015 in exchange for Novartis\u2019 vaccine business. Just a few years ago, GSK had no cancer drugs on the market, but it now boasts four approved treatments and 13 in clinical trials. Last year, the oncology division generated nearly \u00a32 billion in revenue, representing a 43% increase from 2024, with sales of its endometrial cancer medication Jemperli surging by 89%.<\/p>\n","protected":false},"excerpt":{"rendered":"
GSK has announced encouraging findings regarding a new treatment for gynecological cancers as its CEO, Luke Miels, intensifies the company’s focus on drug development. The firm reported that in an early-phase clinical trial, Mocertatug Rezetecan, referred to as Mo-Rez, was able to reduce or eliminate tumors in 62% of patients with ovarian cancer who had […]<\/p>\n","protected":false},"author":2,"featured_media":8021,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[549,725,469,1917,695,937,1399,1918,88,1651],"tags":[],"class_list":["post-8022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uk-business","category-uk-cancer","category-uk-drugs","category-uk-gsk","category-uk-health","category-uk-manufacturing-sector","category-uk-medical-research","category-uk-pharmaceuticals-industry","category-uk","category-uk-women-s-health"],"yoast_head":"\n